Table 5.
SF hydrogel as a delivery vehicle for therapeutic factors.
| Delivery system | Active substance | Application | Fabrication method | Experimental model | Remarks | Reference |
|---|---|---|---|---|---|---|
| pH responsive SF hydrogel | DOX | Breast cancer | Self-assembling | Nude mice tranplanted with MDA-MB-231 cells | Long-term antitumor efficacy | [33], [134] |
| SF hydrogel releasing anti-VEGF | Bevacizu mab | Ocular drug delivery | Sonication | Intravitreal injection into the eyes of Dutch-belted rabbits | Release over 91 days | [137] |
| SF-SWCNT-FA/DOX | DOX- loaded folic acid | Cancer therapy | Blending | KB cell line | pH and temperature- dependentDOX release | [106] |
| SF hydrogel for photo-thermal therapy | Biliverdin | Glioma tumor | Ultrasonication | Balb/c nude mice with subcutaneous glioma | Photo-acoustic and photo-thermal properties | [141] |
| SELPs 815 K | Thymidine kinase and luciferase | Oral cancer | Direct loading | CD-1 mice with squamous cell carcinoma | Prolonged release | [148] |
| SF‐PEGDMA hydrogel | TGF‐β1 and bFGF | Articular cartilage regeneration | Entrapment | Dental pulp | Site specific release | [154] |
| SF hydrogel | VEGF and BMP-2 | Sinus floor augmentation | Entrapment | Rabbit sinus cavity | Slow release of dual factors | [176] |
| Injectable SF hydrogel | Insulin | Diabetes | Direct loading | Diabetic T1DM Wistar rats | Controlled release from porous scaffold | [160] |
| SF and phenylboronic acid /acrylamide hydrogel microneedle | Insulin | Diabetes | Polymerization | Mouse skin | Transdermal insulin delivery | [161] |
| SF hydrogel | BMSCs | Bone regeneration | Blended and sonicated | Calvarial defects in rats | Prolonged survival of BMSCs | [167] |
| SF/pullan composite hydrogel | MSCs | - | HRP and HP enzyme- mediated polymerization | - | Improved mechanical properties, | [170] |